A Prospective, Single-arm, Multi-center Clinical Study of Camrelizumab and Chemotherapy Combined With Endoscopic Surgery in the Treatment of Recurrent Nasopharyngeal Carcinoma
Who is this study for? Patients with recurrent nasopharyngeal carcinoma
What treatments are being studied? Camrelizumab+Chemotherapy+Endoscopic surgery
Status: Recruiting
Location: See all (7) locations...
Intervention Type: Drug, Procedure
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
To explore the effect of Camrelizumab and chemotherapy combining with endoscopic surgery in the treatment of recurrent nasopharyngeal carcinoma.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Pathologically confirmed recurrent nasopharyngeal carcinoma
• American Joint Committee on Cancer recurrent rT2(recurrent T2)(including deep parapharyngeal space), recurrent T3, recurrent T4 which can be surgically removed
• Age ≥18 years old
• Informed consent signed
• With or without lymph node metastasis, which can be surgically removed
• No massive hemorrhage risk recently
• No distant metastasis
• ≥6 months from initial radiotherapy to recurrence
• Radical radiation only once
• Sufficient organ function
• Eastern Cooperative Oncology Group score 0-2
Locations
Other Locations
China
Fujian Medical University Union Hospital
NOT_YET_RECRUITING
Fuzhou
Fujian Provincial Hospital
NOT_YET_RECRUITING
Fuzhou
The First Affiliated Hospital of Nanchang University
NOT_YET_RECRUITING
Nanchang
The People's Hospital of Guangxi Zhuang Autonomous Region
NOT_YET_RECRUITING
Nanning
Eye& ENT Hospital, Fudan University
RECRUITING
Shanghai
Shanghai Zhongshan Hospital,Fudan University
NOT_YET_RECRUITING
Shanghai
Shenzhen Second People's Hospital
NOT_YET_RECRUITING
Shenzhen
Contact Information
Primary
Xiaole Song, MD
jxfxsxl@163.com
15821388769
Time Frame
Start Date: 2021-08-10
Estimated Completion Date: 2025-08-10
Participants
Target number of participants: 100
Treatments
Experimental: Camrelizumab and chemotherapy combined with endoscopic surgery
Camrelizumab and chemotherapy combined with endoscopic surgery
Related Therapeutic Areas
Sponsors
Collaborators: Chinese Academy of Medical Sciences
Leads: Eye & ENT Hospital of Fudan University